Comparison · NCT01100502-sae
Brentuximab Vedotin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Brentuximab Vedotin vs Placebo: serious adverse events. Trial comparisons, record NCT01100502-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01100502-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.257 | 0.197 | 0.329 | wilson | |
| Risk in group 2 | 0.131 | 0.0875 | 0.192 | wilson | |
| Risk difference, group 1 minus group 2 | 0.126 | 0.0404 | 0.21 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.96 | 1.22 | 3.15 | log | |
| Odds ratio, group 1 over group 2 | 2.3 | 1.29 | 4.08 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Brentuximab Vedotin than on Placebo | 7.92 | 4.77 | 24.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Brentuximab Vedotin | brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion | 43 | 167 | EG001 |
| Group 2 | Placebo | placebo every 3 weeks by IV infusion | 21 | 160 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Non-serious adverse events were followed for up to 15 months. Serious adverse event data were collected for up to approximately 10 years (116 months).
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- NCT number
- NCT01100502
- Phases
- PHASE3
- Conditions
- Disease, Hodgkin
- Interventions
- brentuximab vedotin, placebo
- Lead sponsor
- Seagen Inc.
- Results first posted
- 2015-11-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01100502?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01100502-sae